Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Interest Expenses (2016 - 2017)

Heron Therapeutics' Interest Expenses history spans 4 years, with the latest figure at $3.6 million for Q3 2017.

  • For Q3 2017, Interest Expenses changed N/A year-over-year to $3.6 million; the TTM value through Jun 2018 reached $2.0 million, down 43.06%, while the annual FY2025 figure was $9.6 million, 59.23% up from the prior year.
  • Interest Expenses reached $3.6 million in Q3 2017 per HRTX's latest filing, roughly flat from $3.6 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3.6 million in Q1 2017 to a low of $201000.0 in Q1 2013.
  • Average Interest Expenses over 3 years is $1.9 million, with a median of $2.0 million recorded in 2016.
  • The largest YoY upside for Interest Expenses was 0.5% in 2013 against a maximum downside of 0.5% in 2013.
  • A 3-year view of Interest Expenses shows it stood at $209000.0 in 2013, then surged by 880.86% to $2.0 million in 2016, then soared by 75.61% to $3.6 million in 2017.
  • Per Business Quant, the three most recent readings for HRTX's Interest Expenses are $3.6 million (Q3 2017), $3.6 million (Q2 2017), and $3.6 million (Q1 2017).